Skip to main content
Log in

Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials

Quality of Life Research Aims and scope Submit manuscript

Abstract

Introduction

The chief therapeutic goal in metastatic prostate cancer is prolongation of survival with good quality of life . Quality of life (health-related) is often used as an endpoint parameter in phase III trials in metastatic prostate cancer, but the value of using HRQOL in this context has not been assessed to date.

Methods

In order to evaluate the role of HRQOL assessment in contemporary phase III trials in prostate cancer, we searched the PubMed database to identify publications presenting the results of these trials on systemic therapies for prostate cancer published between January 2000 and December 2015. The analysis was separately presented in ten leading journals. We searched for companion papers reporting on QOL separately.

Results

We identified 84 studies which included a total of 57,193 patients in ten leading journals and 27 studies (7270 patients) in other journals. HRQOL parameters were described or mentioned in the main publication in 25 publications and four companions in total. There was no obvious trend in quality of life reported over two 8-year periods . The explicit statistical comparisons were reported in 22/25 cases (88 %), with significant difference in only 10/25 (40 %) studies and in eight cases (80 %) was conducive to the examined arm. There was no significant association between improvements in HRQOL and improvements in overall survival (OS) or any other primary endpoint in the analyzed studies. Only one study was found which presented the difference in quality of life with no difference in the primary endpoint.

Conclusions

HRQOL is an indicator of benefit during treatment of patients with metastatic prostate cancer, but it is unlikely that HRQOL results can help clinicians choose between treatments given that they are not correlated with changes in OS or at other primary endpoints.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Mould, R. (2008). Cancer statistics overview with special reference to prostate, colon and rectum, lung, breast and cervix uteri. Nowotwory Journal of Oncology, 58, 213–220.

    Google Scholar 

  2. Wojciechowska, U., Didkowska, J., & Zatoński, W. (2012). Nowotwory złośliwe w Polsce. Warszawa: Centrum Onkologii Instytut.

    Google Scholar 

  3. American Cancer Society. (2004). Cancer facts and figures-2004 Atlanta. Atlanta: American Cancer Society.

    Google Scholar 

  4. The World Health Organization Quality of Life assessment. (1995). (WHOQOL): Position paper from the World Health Organization. Social Science and Medicine, 41, 1403–1409.

    Article  Google Scholar 

  5. Greenfield, S., & Nelson, E. C. (1992). Recent developments and future issues in the use of health status assessment measures in clinical settings. Medical Care, 30, 23–41.

    Article  Google Scholar 

  6. Michael, M., & Tannock, I. F. (1998). Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment. Canadian Medical Association Journal, 158, 1727–1734.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Minasian, L. M., O’Mara, A. M., Reeve, B. B., et al. (2007). Health-related quality of life and symptom management research sponsored by the National Cancer Institute. Journal of Clinical Oncology, 25, 5128–5132.

    Article  PubMed  Google Scholar 

  8. Crook, J. M., O’Callaghan, C. J., Duncan, G., et al. (2012). Intermittent androgen suppression for rising PSA level after radiotherapy. New England Journal of Medicine, 367, 895–903.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Scher, H. I., Fizazi, K., Saad, F., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine, 367, 1187–1197.

    Article  CAS  PubMed  Google Scholar 

  10. Tannock, I. F., de Wit, R., Berry, W. R., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine, 351, 1502–1512.

    Article  CAS  PubMed  Google Scholar 

  11. Loriot, Y., Miller, K., Sternberg, C. N., et al. (2015). Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): Results from a randomised, phase 3 trial. Lancet Oncology, 16, 509–521.

    Article  CAS  PubMed  Google Scholar 

  12. Basch, E., Autio, K., Ryan, C. J., et al. (2013). Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: Patient-reported outcome results of a randomised phase 3 trial. Lancet Oncology, 14, 1193–1199.

    Article  CAS  PubMed  Google Scholar 

  13. Fosså, S. D., Slee, P. H., Brausi, M., et al. (2001). Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A phase III study of the European organization for research and treatment of cancer genitourinary group. Journal of Clinical Oncology, 19, 62–71.

    Article  PubMed  Google Scholar 

  14. Harland, S., Staffurth, J., Molina, A., et al. (2013). Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. European Journal of Cancer, 49, 3648–3657.

    Article  CAS  PubMed  Google Scholar 

  15. Cella, D., Ivanescu, C., Holmstrom, S., Bui, C. N., Spalding, J., & Fizazi, K. (2015). Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: Additional analyses from the AFFIRM randomized clinical trial. Annals of Oncology, 26, 179–185.

    Article  CAS  PubMed  Google Scholar 

  16. Nelson, J. B., Fizazi, K., Miller, K., et al. (2012). Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer, 118, 5709–5718.

    Article  CAS  PubMed  Google Scholar 

  17. Abratt, R. P., Brune, D., Dimopoulos, M. A., et al. (2004). Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Annals of Oncology, 15, 1613–1621.

    Article  CAS  PubMed  Google Scholar 

  18. Shamash, J., Powles, T., Sarker, S. J., et al. (2011). A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: Immediate vs deferred Diethylstilbestrol. British Journal of Cancer, 104, 620–628.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Fizazi, K., Lesaunier, F., Delva, R., et al. (2012). A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial. European Journal of Cancer, 48, 209–217.

    Article  CAS  PubMed  Google Scholar 

  20. Small, E. J., Meyer, M., Marshall, M. E., et al. (2000). Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. Journal of Clinical Oncology, 18, 1440–1450.

    Article  CAS  PubMed  Google Scholar 

  21. Fizazi, K., Higano, C. S., Nelson, J. B., et al. (2013). Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 31, 1740–1747.

    Article  CAS  PubMed  Google Scholar 

  22. Vitolins, M. Z., Griffin, L., Tomlinson, W. V., et al. (2013). Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer. Journal of Clinical Oncology, 31, 4092–4098.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Brundage, M., Sydes, M. R., Parulekar, W. R., et al. (2015). Impact of radiotherapy when added to androgen-deprivation therapy for locally advanced prostate cancer: Long-term quality-of-life outcomes from the NCIC CTG PR3/MRC PR07 randomized trial. Journal of Clinical Oncology, 33, 2151–2157.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Ernst, D. S., Tannock, I. F., Winquist, E. W., et al. (2003). Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. Journal of Clinical Oncology, 21, 3335–3342.

    Article  CAS  PubMed  Google Scholar 

  25. Saad, F., Gleason, D. M., Murray, R., et al. (2002). Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute, 94, 1458–1468.

    Article  CAS  PubMed  Google Scholar 

  26. Fransson, P., Lund, J. A., Damber, J. E., et al. (2009). Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncology, 10, 370–380.

    Article  PubMed  Google Scholar 

  27. Denham, J. W., Wilcox, C., Joseph, D., et al. (2012). Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncology, 13, 1260–1270.

    Article  CAS  PubMed  Google Scholar 

  28. Goodwin, P. J., Black, J. T., Bordeleau, L. J., & Ganz, P. A. (2003). Health-related quality-of-life measurement in randomized clinical trials in breast cancer–taking stock. Journal of the National Cancer Institute, 95, 263–281.

    Article  PubMed  Google Scholar 

  29. Simes, R. J., Greatorex, V., & Gebski, V. J. (1998). Practical approaches to minimize problems with missing quality of life data. Statistics in Medicine, 17, 725–737.

    Article  CAS  PubMed  Google Scholar 

  30. Aaronson, N. K., Ahmedzai, S., Berman, B., et al. (1993). The Eurpean Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365–376.

    Article  CAS  PubMed  Google Scholar 

  31. Fayers, P., & Bottomley, A. (2002). Quality of life research within the EORTC—the EORTC QLQ-C30. European Journal of Cancer, 38, 125–133.

    Article  Google Scholar 

  32. Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et al. (1993). The functional assessment of cancer therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11, 570–579.

    Article  CAS  PubMed  Google Scholar 

  33. Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997). Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology, 50(6), 920–928.

    Article  CAS  PubMed  Google Scholar 

  34. King, M., Bell, M. L., Costa, D., Butow, P., & Oh, B. (2014). The quality of life questionnaire core 30 (QLQ-C30) and functional assessment of cancer-general (FACT-G) differ in responsiveness, relative efficiency, and therefore required sample size. Journal of Clinical Epidemiology, 67, 100–107.

    Article  PubMed  Google Scholar 

  35. Bottomley, A., & Aaronson, N. K. (2007). International perspective on health-related quality of-life research in cancer clinical trials: The European Organisation for Research and Treatment of Cancer experience. Journal of Clinical Oncology, 25, 5082–5086.

    Article  PubMed  Google Scholar 

  36. Adamowicz, K., Jassem, J., Katz, A., & Saad, E. D. (2012). Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials. Cancer Treatment Reviews, 38, 554–558.

    Article  PubMed  Google Scholar 

  37. Saad, E. D., Adamowicz, K., Katz, A., & Jassem, J. (2012). Assessment of quality of life in advanced non-small-cell lung cancer: An overview of recent randomized trials. Cancer Treatment Reviews, 38, 807–814.

    Article  PubMed  Google Scholar 

  38. Montazeri, A. (2008). Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007. Journal of Experimental and Clinical Cancer Research, 27, 32.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Dancey, J., Zee, B., Osoba, D., et al. (1997). Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Quality of Life Research, 6, 151–158.

    Article  CAS  PubMed  Google Scholar 

  40. Montazeri, A. (2009). Quality of life data as prognostic indicators of survival in cancer patients: An overview of the literature from 1982 to 2008. Health Qual Life Outcomes, 7, 102.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Van Steen, K., Curran, D., Kramer, J., et al. (2002). Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: Identification and impact on model selection. Statistics in Medicine, 21, 3865–3884.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Krzysztof Adamowicz.

Ethics declarations

Conflict of interests

The author declares no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adamowicz, K. Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials. Qual Life Res 26, 813–822 (2017). https://doi.org/10.1007/s11136-016-1429-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11136-016-1429-9

Keywords

Navigation